Thoratec HeartMate Gradual Roll-Out, Center Criteria Counseled By MCAC
This article was originally published in The Gray Sheet
Executive Summary
Thoratec expects the Centers for Medicare & Medicaid Services to announce plans for national coverage of the HeartMate VE left ventricular assist device as a destination therapy by June
You may also be interested in...
Thoratec’s Nelson Challenges CMS Basis For Setting LVAD Facility Criteria
CMS' criteria for approving facility coverage of "destination" left-ventricular assist device implants are not rooted in scientific evidence, according to Thoratec Cardiovascular Division President Jeff Nelson
Thoratec’s Nelson Challenges CMS Basis For Setting LVAD Facility Criteria
CMS' criteria for approving facility coverage of "destination" left-ventricular assist device implants are not rooted in scientific evidence, according to Thoratec Cardiovascular Division President Jeff Nelson
Permanent LVAD Implants Appropriate For End-Stage Heart Failure – CMS
Left-ventricular assist device implants for destination therapy will be limited to 60 U.S. centers under the terms of a positive CMS national coverage determination for the therapy, Thoratec estimates